<DOC>
	<DOCNO>NCT01145755</DOCNO>
	<brief_summary>This 6-week study treatment evaluate safety effectiveness AZD2066 patient major depressive disorder .</brief_summary>
	<brief_title>6-week Study Treatment Evaluate Safety Effectiveness AZD2066 Patients With Major Depressive Disorder</brief_title>
	<detailed_description>A Phase IIa , Multi-centre , Randomized , Double-Blind , Double-Dummy , Active Placebo Controlled , parallel Group Study Assess Efficacy Safety AZD2066 6 week treatment Patients Major Depressive Disorder - D0475C00020 .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Provision sign , write , date Informed Consent Documented primary clinical diagnosis Major Depressive Disorder Patients secondary psychiatric disorder include bipolar disorder , psychotic disorder ( i.e . schizophrenia , schizoaffective disorder , depression psychotic feature ) , GAD social anxiety disorder Patients whose current episode depression start less 4 week enrollment History inadequate response antidepressant current depressive episode</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Depression</keyword>
</DOC>